Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates

分组1 - Nurix Therapeutics reported a quarterly loss of $1.03 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.84, and a decline from a loss of $0.67 per share a year ago, indicating an earnings surprise of -22.62% [1] - The company posted revenues of $7.89 million for the quarter ended August 2025, missing the Zacks Consensus Estimate by 57.71%, and a decrease from year-ago revenues of $12.59 million [2] - The stock has underperformed significantly, losing about 47% since the beginning of the year compared to the S&P 500's gain of 14.8% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$0.91 on revenues of $12.6 million, and for the current fiscal year, it is -$2.95 on revenues of $87.54 million [7] - The Medical - Biomedical and Genetics industry, to which Nurix Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]